Evaluate the Accuracy of a COPD Screening Algorithm Model
NCT ID: NCT06109974
Last Updated: 2024-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2022-09-13
2024-01-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detect and Infer the Severity of COPD by Intelligent Terminal Device
NCT05551169
The Cohort Study for Chronic Obstructive Pulmonary Disease (COPD) in China
NCT03044847
The China National COPD Screening Program
NCT05480176
Study on the Etiology, Risk Factors and Pathogenesis of COPD Based on Clinical Bioinformatics
NCT05069194
Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm
NCT07223749
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, 404 residents at high risk of COPD (COPD-PS score≥5) will be enrolled. Questionnaires related to COPD will be collected, subjects will undergo pulmonary function tests and electrocardiogram. Physiological parameters such as oxygen saturation and heart rate will be collected by a wearable device 3 times for 2 minutes each time, and coughing sound will be collected. As spirometry is the gold standard for the diagnosis of COPD, the accuracy of COPD diagnosis algorithm model by intelligent terminal devices will be verified.
The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2022-083). Any protocol modifications will be submitted for the IRB review and approval.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with high risk of COPD
no intervention
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants at high risk of COPD (COPD-PS score ≥5).
3. Able to carry out daily activities and wear wearable devices.
4. Willing to participate in the study, willing to comply with the study protocol, and have the ability to sign informed consent.
5. Possess mobile communication equipment, which can meet the requirement of installing wearable device applications and recording function.
Exclusion Criteria
2. lobectomy and/or lung transplantation, pleural disease.
3. Complicated with serious underlying diseases, including severe mental illness, intellectually impaired diseases, neurological disease (resulting in limb movement disorder), malignant tumor (PS score \> 2), chronic liver disease (transaminase \> 3 times the upper limit of normal), heart failure (NYHA\> Grade 3), autoimmune disease, chronic kidney disease (CKD-5), unstable coronary artery disease, arrhythmia (atrial fibrillation, atrial flutter, severe ventricular arrhythmia), congenital heart disease, pulmonary hypertension, etc., or life expectancy of less than 6 months.
4. Malnutrition (BMI\<18 kg/m2).
5. Bilateral wrist and hand edema, wrist soft tissue injury, inability to wear a watch/bracelet due to incomplete skin.
6. Dual upper limb pigmentation or abnormal blood supply (occlusion, thrombosis, trauma, etc.).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Civil Aviation General Hospital
OTHER
Shichahai Community Health Service Center of Xicheng District Beijing
UNKNOWN
The Hospital of Changping District Beijing
UNKNOWN
Baizhifang Community Health Service Center of Xicheng District Beijing
UNKNOWN
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guangfa Wang
Prof. & MD.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guangfa Wang, MD
Role: STUDY_CHAIR
Peking University First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baizhifang Community Health Service Center of Xicheng District Beijing
Beijing, Beijing Municipality, China
Civil Aviation General Hospita
Beijing, Beijing Municipality, China
Guangfa Wang
Beijing, Beijing Municipality, China
Shichahai community health service center
Beijing, Beijing Municipality, China
The Hospital of Changping District Beijing
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022083-20230810
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.